Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Langzhi Group Wanrong Pharmaceutical Co., Ltd., a core manufacturing subsidiary of the Langzhi Group, is a comprehensive pharmaceutical enterprise based in Shanxi Province, China. The company specializes in the development and large-scale production of Traditional Chinese Medicine (TCM) and chemical drug formulations, holding hundreds of production approvals across various dosage forms such as capsules, tablets, and injections. Its flagship product, Zhi Zhu Kuan Zhong Capsules, is a prominent TCM treatment for functional dyspepsia that has achieved significant market share and international recognition. Wanrong Pharmaceutical operates advanced GMP-certified facilities and is integrated into Langzhi Group's broader ecosystem, which spans from medicinal herb cultivation to digital healthcare solutions. The company focuses on therapeutic areas including gastroenterology, cardiovascular health, and respiratory medicine, serving thousands of hospitals and pharmacies throughout China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lanzhi Group Wanrong Pharmaceutical.